Evicenter
P&T meetings

Imsidolimab

Generalized pustular psoriasis

Regulatory submission
BLA submitted December 2025
Last updated
85 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

1 evidence topic · 2 sources

Pharmacokinetics: phase 1 healthy-volunteer study

“half-life of ANB019 was approximately 28 days for both subcutaneous and intravenous routes of administration, with bioavailability of approximately 90%.” (opens the source at this quote in a new tab)

“Median terminal half life ranged between 597 and 689 hours (25 to 29 days).” (opens the source at this quote in a new tab)

“Bioavailability was approximately 90%” (opens the source at this quote in a new tab)